50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH

Size: px
Start display at page:

Download "50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH"

Transcription

1

2 50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S [(1S,2S)-2- [(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S, 26S)-3-[(R) ]-11,20,21, [(R)-1- ] ,5,8,14,17, [4-[5-(4- ) -3- ] ]-1,4,7,13,16,22- [ ,13 ] -6- ]-1,2- ]-2- S o d i u m 5 - [ ( 1 S, 2 S ) [(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)- 3-[(R)-2- carbamoyl-1-hydroxyethyl]-11,20,21,25-tetrahydroxy-15-[(r)- 1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[4-[5- ( 4- pentyloxyphenyl) isoxazol-3-yl] benzoylamino] - 1,4,7,13,16,22-hexaazatri- cyclo[ ,13 ]heptacos-6-yl]- 1,2-dihydroxyethyl] -2-hydroxyphenyl sulfate 1

3 mg 75mg (1) 2 150mg mg mg 50mg mg 75mg 30 75mg 1 150mg/ 2

4 mg 50mg 75mg mg 1 25mg 50mg 1 50mg 75mg 1 75mg mg mg mg 75mg 30 75mg 1 Coleophoma empetri echinocandin B 3

5 B AMPH-B 5- FC MCZ FLCZ ITCZ AMPH-B MCZ FLCZ 3 AMPH-B 1,3- -D-glucan Caspofungin acetate Cancidas Merck 6 UV IR 1 H-NMR 13 C-NMR X ph mg/ml pka ph ph UV IR 13 C-NMR ph ph 4

6 ph % / /27 25 /60%RH/ / /60%RH/ /27 40 /75%RH/ /6 / /3 / / /40 5

7 2 5w/v% / 5 15mg/mL mg/mL ph mg/kg mg/kg 125mg/kg 250mg/kg 200mg/kg mg/kg/ mg/kg/ mg/kg/ GOT GPT 4 32mg/kg/ mg/kg/

8 mg/kg/ mg/kg/ mg/kg/ mg/kg/ mg/kg/ mg/kg/ 10mg/kg/ mg/kg/ 32mg/kg/ GPT 10mg/kg/ 32mg/kg/ 10mg/kg/ 3.2mg/kg/ 32mg/kg/ 32mg/kg/ mg/kg/ 32mg/kg/ GPT 10mg/kg/ 32mg/kg/ mg/kg/ 32mg/kg/ 1 32mg/kg/ 10mg/kg/ 32mg/kg/ mg/kg/ 32mg/kg/ 10mg/kg/ 32mg/kg/ 10mg/kg/ % AMPH-B 0.01%

9 0.025% 0.425% 0.05% 0.01% AMPH-B 0.425% 1.7% ASA PCA PCA PCA mg AUC Cmax life threatening 300mg 1 300mg 1 150mg 1 300mg AUC AUC mg/kg AST GOT ALT GPT 26 32mg/kg Na Cl 10mg/kg Altered cell foci GST-P Glutathion S-transferase placental form PCNA Proliferating cell nuclear 8

10 antigen mg/kg 39 FLCZ ITCZ B AMPH-B Candida Saccharomyces cerevisiae Aspergillus Cryptococcus neoformans Trichosporon Fusarium solani Pseudallescheria boydii 1 Candida Aspergillus MIC µg/ml MIC µg/mL 9

11 1 MIC Candida MIC ph HSA MIC A. fumigatus MIC ph ph8 HSA MIC HSA MIC 1 MFC C.albicans C.glabrata C.krusei AMPH-B C.tropicalis C.guilliermondii 64µg/mL Aspergillus C. albicans FP AMPH-B Candida MIC AMPH-B AMPH-B AMPH-B 1 C. albicans 1 2 1,3- -D-glucan 2 6 cyclophosphamide C.albicans mg/kg mg/kg 1.0mg/kg 22 AMPH-B FLCZ mg/kg ITCZ 20mg/kg Cyclophosphamide hydrocortisone 5-fluorouracil C. albicans 24 10

12 AMPH-B ED 50 1 FLCZ ED AMPH-B FLCZ C. albicans AMPH-B 0.5mg/kg 0.25mg/kg FLCZ 4.0mg/kg 3 C. albicans 0.16µg/mL 0.26µg/mL 4 5 cyclophosphamide C.albicans mg/kg 7 0.5mg/kg 1.0 mg/kg 22 AMPH-B ITCZ mg/kg FLCZ 20mg/kg Hydrocortisone 5-fluorouracil A.fumigatus 24 AMPH-B ED mg/kg AMPH-B 5 A.fumigatus 0.55µg/mL 0.80µg/mL 4 2mg/kg/ 5mg/kg/ 8 8 5mg/kg/ 6 3 M1 M2 M5 MIC M1 M2 M5 1/128 7 C. albicans M1 M2 7 11

13 in vitro AMPH-B ITCZ FLCZ C. albicans % % % A. fumigatus % % 4 13 % C. neoformans 18 AMPH-B % 6 33 % ITCZ % 8 A. fumigatus AMPH-B 1mg/kg AMPH-B 0.25mg/kg g/ml g/ml in vivo g/ml g/ml in vivo 9 Candida Aspergillus MIC 90 MIC 50 4 Candida Aspergillus Candida Aspergillus 12

14 Candida Aspergillus ICR SD mg/kg AUC 1mg/kg 1 AUC t 1/ mg/kg t 1/2 AUC mg/kg AUC t 1/2 AUC 14 C 1mg/kg % 2 M8 M9 M8 M C 1mg/kg % % C 1mg/kg 7 1/10 13

15 in vitro 99.7% 4% µg/mL 10µg/mL 4% 2% M1 M2 in vitro µg/mL % 14 C TLC HPLC HPLC/ M1 M2 M3 M5 M6 M8 M9 M10 8 M1 M2 M1 M1 M1 M2 M1 COMT catechol O- methyltransferase M2 M2 M5 CYP1A2 2B6 2C 3A4 14 C 1mg/kg % 14.4% 0.0% 1mg/kg % 15.2% % 14 C 8 14 C 1mg/kg mg 2 Cmax AUC 0- M1 14

16 M2 0.05µg/mL mg mg 1 AUC 0- M1 50 mg mg µg/mL M2 M1 M2 1% 6 25mg t 1/ mg t 1/ % M1 M mg mg Cmax Cmin 24 2 t 1/2 t 1/ t 1/ PPK 2- CL T mg 30 2 CL T CL T CL T 6 14 C 28.3mg 3.05MBq 1 Cmax 2.97µg/mL AUC µg h/ml t 1/ Cmax 2.29µg eq./ml AUC µg eq. h/ml t 1/ % 43.80% 4 15

17 µg eq./ml 0.023µg eq./ml µg eq./ml 2 12 HPLC M5 14 C 0.70% M5 3.62% 11.71% M3 1.75% M % 400mg/ mg CL T t 1/2 1 7 AUC 0-24h mg/kg mg CL T t 1/2 1 7 AUC 0-24h AUC Cmax Cmin kg 82.8kg CL T CYP 6.5µg/mL CYP1A2 2C9 2C19 2D6 2E1 3A 65µg/mL CYP3A 99.8% CYP3A 16

18 14 C M5 M13 2 M5 2 M5 CYP1A2 2B6 2C 3A4 M13 CYP1A1 1A2 2A6 3A4 CYP M % CYP 1/100 A IC 50 31µmol/L 10µmol/L IC µmol/L 1/200 A M5 M13 A 100µmol/L 400mg/ CL T AUC P P P MRP2 A 30mg/kg A mg/ 5mg/kg Cmax/Dose AUC 0-12 /Dose 90% % Cmax AUC 0-24 AUC 0-90% % 1 17

19 99.8% Kragh-Hansen Biochem J 225(3); , PPK C 8 GOT 219IU GPT 153IU Al-P 1428IU -GTP 253IU CL T HIV HIV CYP3A4 CYP P in vitro CYP P ADME (1) 1 P-1 2.5mg 5mg 12.5mg 25mg 50mg BUN CPK CRP 1 18

20 IgE PCA in vitro 50mg 2 P Aspergillus 25mg BUN 2 1 BUN ng/mL 0.81ng/mL 0.2ng/mL ng/mL FJ Aspergillus Candida X 12.5mg 25mg

21 12.5mg 30 25mg mg 50mg mg 25mg 30 50mg mg 50mg 75mg mg mg 1 150mg kg mg 7 50mg 7 75mg mg 1 150mg 13 25mg 5 50mg 4 75mg % 24/ % 11/14 25mg 50mg 75mg 100mg 150mg 28.6% 2/7 71.4% 5/7 57.1% 8/14 0% 0/1 69.2% 9/13 25mg 50mg 75mg 60% 3/5 100% 4/4 80% 4/5 54.5% 12/22 60% 6/ % 6/9 0% 0/1 71.4% 5/7 100% 6/6 0% 0/1 60.6% 20/33 20

22 65.2% 15/ mg 2 AMPH-B FLCZ 75mg 1 AMPH-B Aspergillus A. fumigatus Candida C. albicans 57.9% 11/ % 4/7 non-albicans Candida species C. glabrata C. tropicalis C. krusei 4 3 Chemotherapy 39: 687, % % % BUN 7 K K GPT ALT 6 GOT AST LDH CRP 5 ALP 4 -GTP % 21 ALP BUN 3 GPT ALT -GTP % LDH BUN K

23 1 G-CSF 3 2 FJ Aspergillus Candida 3 X 50mg 150mg mg mg 75mg 30 75mg mg/ GOT GPT Al-P -GTP (2) / FLCZ 22

24 FLCZ mg 12.5mg 25mg 50mg 75mg 100mg 150mg 200mg C 2 Southwest Oncology Group (SWOG Toxicity Criteria Invetigational New Drugs 10: , Grade /mm C C mg 8 25mg 9 50mg 9 75mg 9 100mg 9 150mg mg 8 C % C 3 25% 7 11% C 6 50% 35 57% C 3 25% 14 23% C 3 25% 12 19% C 3 25% 12 19% C 1 8% 17 27% C 4 33% 17 27% C 8 67% 35 57% C 6 50% 23 37% K C 4 33% 15 24% P C 3 25% 10 16% C 3 25% 18 29% C 3 25% 13 21% C 4 33% 20 32% C % C % % C % 73 C Grade 3 50mg 200mg K 150mg 200mg 200mg mg C 41.7% 5/ % 15/ mg 25% 2/8 25mg 33.3% 3/9 50mg 22.2% 2/9 75mg 33.3% 3/9 100mg 22.2% 2/9 150mg 10% 1/10 200mg 25% 2/8 23

25 / 5 1 FG mg/kg 4mg/kg 6mg/kg 8mg/kg SWOG Toxicity Criteria 3 Grade /mm mg/kg 10 4mg/kg 10 6mg/kg 8 8mg/kg % % K % % % % % % % % % % % % Mg % % % % % % GPT ALT % % % % BUN % GOT AST % % % 21 3mg/kg Ca 1 4mg/kg mg/kg mg/kg Grade 3 1 8mg/kg 3mg/kg 30% 3/10 4mg/kg 30% 3/10 6mg/kg 37.5% 3/8 8mg/kg 25% 2/ MED HIV AIDS

26 10 65% MED 50mg 25mg 12.5mg 3 50mg 25mg 12.5mg / mg/ 75mg 100mg/ 12.5mg 75mg 100mg 120 Candida mg 25mg 50mg 75mg 100mg C. albicans 1 C. albicans C. tropicalis 12.5mg 66.7% 12/18 25mg 92.3% 12/13 50mg 93.3% 14/15 75mg 100% 19/19 100mg 100% 19/19 Cochran-Armitage p= mg 65% MED 12.5mg/ % % % % % % 9 7.5% 9 7.5% 8 6.7% 7 5.8% 5 4.2% 5 4.2% 5 4.2% 5 4.2% % 12.5mg % mg % 10 GOT AST mg % mg % mg % 13 3 ALP 1 13 AIDS 3 2 HIV 1 25

27 % AIDS K mg FG Aspergillus De novo 48 Efficacy failure 72 Toxicity failure De novo 50 mg 40kg 1mg/kg mg 0.5mg/kg 100mg 2mg/kg Efficacy failure 75 mg 40kg 1.5mg/kg 150mg 3mg/kg 150mg 7 75mg 1.5mg/kg 225mg 4.5mg/kg 200mg kg kg % A. fumigatus % A. flavus % Aspergillus % De novo 14 Efficacy failure 136 Toxicity failure 11 Efficacy failure 125 AMPH-B 89 5 AMPH-B n= mg mg n=

28 mg mg mg/kg mg/kg % % % % 63.7% 95% % De novo 92.9% n=14 Efficacy failure 60.8% n=125 Efficacy failure 36.4% n=11 Toxicity failure 100% n=7 51 De novo 1 Efficacy failure 50mg 73.3% 11/15 50mg 50.0% 3/ mg 69.0% 40/ mg 64.7% 11/ mg 64.3% 18/ mg 75.0% 6/ mg 45.8% 11/24 A. fumigatus 59.7% 40/67 A. flavus 71.4% 15/21 A. niger 85.7% 6/ % % % % 1 0.6% % % 9 5.7% % % % % K % % % % % % % % Mg % % % % % K % % % % % GOT AST % GPT ALT % 33.9% 63/ % % 7 3.8% 6 3.2% ALP 6 3.2% % 47/ % 16/ % % % % 9 4.8% 8 4.3% 5 2.7% 4 2.2% 1 27

29 % % % % % % % 8 4.3% 5 2.7% % 4 2.2% 3 1.6% 2 1.1% 8 3 FG C.albicans non-albicans Candida species 10 7 FG De novo 48 Efficacy failure 5 De novo 50 mg 40kg 1mg/kg mg 0.5mg/kg 100mg 2mg/kg Efficacy failure 2 150mg 3mg/kg 5 50mg 1mg/kg 200mg 4mg/kg 200mg Germ tube non-albicans Candida species 100mg 2mg/kg kg kg % % C. albicans % non-albicans Candida species % Candida % De novo 146 Efficacy failure 63 Efficacy failure 35 AMPH-B AMPH-B 18 AMPH-B 5-FC

30 n= mg mg n= mg/kg mg/kg 7 FG % % % % 82.8% 95% % De novo 89.0% n=146 Efficacy failure 62.9% n=35 Efficacy failure 75.0% n=28 De novo 7 4.8% Efficacy failure % Efficacy failure 2 7.1% 50mg 72.2% 13/18 50mg 85.3% 64/ mg 87.0% 40/ mg 81.4% 35/ mg 88.9% 16/ mg 57.1% 4/ mg 50% 1/2 C. albicans 86.8% 118/136 non-albicans Candida species 78.9% 60/76 Candida 66.7% 8/ % % % % 1 0.5% % % % % % % Mg % K % % % % % % % % % 47.6% 119/250 GOT AST 10.8% Mg 9.2% GPT ALT 8.8% 8.4% ALP 8.4% Ca 7.6% % 109/ % 10/ % % 9 3.6% 7 2.8% 3 1.2% % % % % 9 3.6% 7 2.8% 6 2.4% K 5 2.0% 4 1.6% K 4 1.6% 3 1.2% 2 0.8% ALP 2 0.8% 29

31 FLCZ 6 50mg FLCZ 400mg 50kg 1mg/kg FLCZ 8mg/kg /mm FLCZ FLCZ FLCZ FLCZ FLCZ FLCZ mg/ mg/ FLCZ mg/ mg/ mg/kg/ mg/kg/ FLCZ mg/kg/ mg/kg/ mg/kg/ mg/kg/ FLCZ mg/kg/ /kg/ % 340/425 FLCZ 73.5% 336/ % 95% 0.9% 12.0% 95% 0% FLCZ 1.6% 7/425 FLCZ 2.4% 11/ % 5/425 FLCZ 1.8% 8/ % 2/425 FLCZ 0.7% 3/ % 4/425 FLCZ 0.4% 2/ % 1/425 FLCZ 1.6% 7/457 FLCZ Fisher 30

32 p= % 253/425 FLCZ 65.2% 298/ % 52.0% FLCZ 54.3% 40.9% FLCZ 37.2% 36.0% FLCZ 40.5% 32.9% FLCZ 33.9% 31.5% FLCZ 35.0% 24.0% FLCZ 27.8% 24.9% FLCZ 26.0% 26.6% FLCZ 24.5% 21.9% FLCZ 25.6% 77.9% FLCZ 80.5% 74.1% FLCZ 78.6% 70.6% FLCZ 68.9% 66.4% FLCZ 67.4% 52.7% FLCZ 50.5% 30.4% FLCZ 31.3% 28.5% FLCZ 31.1% 77.9% FLCZ 75.7% 74.8% FLCZ 70.2% 40.5% FLCZ 42.2% Mg 53.2% FLCZ 58.6% K 50.1% FLCZ 51.4% 27.3% FLCZ 24.5% 42.8% FLCZ 36.5% 35.8% FLCZ 32.4% 24.2% FLCZ 26.0% 42.8% FLCZ 40.9% 15.1% 64/425 FLCZ 16.8% 77/ % % 9 2.1% K 8 1.9% P 7 1.6% 6 1.4% Mg 5 1.2% FLCZ % % % GOT AST GPT ALT 9 2.0% K 8 1.8% 7 1.5% Mg 6 1.3% 2.6% 11/425 FLCZ 3.5% 16/ % FLCZ % FLCZ % FLCZ % 1% 3.3% FLCZ 2.8% 3.1% FLCZ 1.3% 1.9% FLCZ 0% 2.1% FLCZ 0.7% 1.9% FLCZ 0.4% 0.7% FLCZ 1.3% 0.2% FLCZ 1.3% 0.2% FLCZ 1.1% 1.6% FLCZ 1.3% 0.7% FLCZ 1.8% 1.4% FLCZ 1.1% 0.2% FLCZ 1.3% 0.5% FLCZ 1.3% FLCZ

33 2 GOT AST GPT AST % FLCZ % GOT AST GPT AST mg/dL n=159 FLCZ mg/dL n= mg/dL n=131 FLCZ mg/dL n= mg/dL n=155 FLCZ mg/dL n= mg/dL n=119 FLCZ mg/dL n= mg/dL n=52 FLCZ mg/dL n= % FLCZ % GOT AST GPT AST (1) 14 C (1)- (2)- MTD MTD MED 3 (2)- (2)- 32

34 14 C MTD MTD MED mg mg 150mg 1 1 (2) 33

35 1 Independent Reviewer FDA NDA documents mg/ MTD 12.5mg/ MED 50mg/ 14 C 28.3mg 1 50mg/ 25mg/ 2.5mg/kg 100mg/ 50kg 2mg/kg 1 25mg/

36 MTD 75mg/ 12.5mg 25mg/ 25mg 50mg/ 75mg/ MTD MED 50mg/ 75mg/ MTD 150mg/ 150mg/ mg/ MTD 200mg/ 75mg/ 150mg/ 75mg/ 150mg/ MTD 225mg/ 200mg/ 2 MTD (3) i) mg % 24/42 25mg 50mg 75mg 100mg 150mg 28.6% 2/7 71.4% 5/7 57.1% 8/14 0% 0/1 69.2% 9/ mg/ 35

37 De novo 8 Efficacy failure 9 Toxicity failure 7 91 Efficacy failure % 18/ mg mg mg mg 225mg 300mg 70.0% 7/ % 3/4 100% 4/4 50.0% 1/2 75.0% 3/ mg 66.7% 4/ mg/ mg mg 150mg 6 150mg 150mg 8mg/kg 600mg 300mg ii) 50mg mg 78.6% 11/14 25mg 50mg 75mg 60% 3/5 100% 4/4 80% 4/5 50mg mg mg 50mg 50mg 50 75mg mg mg mg mg 1/1 89.9% 62/ % 37/ % 32/37 100% 7/7 1/3 1/2 150mg/ 5 150mg nonalbicans Candida species 36

38 C. albicans non-albicans Candida species 25mg mg 150mg 75mg 150mg 150mg iii) % % % 21/ mg 25mg 50mg 75mg 150mg 31.3% 5/ % 2/ % 7/ % 7/ mg 46.2% 146/ mg 300mg 25% 10/40 300mg 0/1 150mg 8.2% 26/ mg 7.3% 3/41 150mg Al-P GOT AST GPT ALT mg 150mg 75mg 1 150mg mg 150mg 300mg 150mg 150mg mg 37

39 50 150mg mg Jpn J Antibiotics 42:47-54,1989 Jpn J Antibiotics 46: ,

40 % 6/ % 15/ % 15/ % 141/316 (4) Al-P mg/kg i.v. bolus g/ml 75mg 30 75mg mg 39

41 AUC Cmax (5) Aspergillus Candida Mucor and Rhizopus Cryptococcus neoformance Blastomyces dermatidis Coccidioides immitus Hisoplasma capsulatum Sporothrix schenckii Candida Sporothrix schenckii Aspergillus Candida AMPH-B K AMPH-B 5-FC 5- DNA AMPH-B CYP 14 - MCZ FLCZ ITCZ MCZ FLCZ FLCZ AMPH-B 1980 FLCZ C.albicans HIV Cecil: Textbook of Medicine, 21 st Edition 1,3- -D- 40

42 60.6% 20/ % 15/ AMPH-B 11 AMPH-B AMPH-B 10 AMPH-B 2 Efficacy failure / % 76/ % 21/ % 22/ % Efficacy failure Harrison s Principles of Internal Medicine, 15 th ed ITCZ 6 12 FLCZ AMPH-B

43 5 (6) mg/kg/

44 11.7% 9/ Cmax AUC Cmax Cmin AUC 1mg/kg/ 50mg/ 14 4 GCP GCP GCP mg mg 43

45 50 150mg mg 150mg/ 44

46 mg 75mg mg/ 50mg/ 300mg/ 150mg/ 300mg/ 150mg/ 40% 2/5 150mg/ 150mg/ 150mg/ mg/ 45

47 300mg/ 300mg/ 150mg CL T 300mg/ 50kg 6mg/kg 50kg 1 6mg( )/kg MTD 8mg/kg 25mg ICH

48 X % % in vitro 47

49 in vitro Cryptococcus neoformans Candida albicans Aspergillus fumigatus mg mg Seg. I mg/kg GST-P PCNA 10mg/kg/ 48

50 mg mg 50mg mg 75mg 30 75mg 1 49

51 150mg/ 50

52 mg 75mg mg/kg 100mg/kg 10 1

1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)

1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2) 1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /

More information

2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na

2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na 2.7.4 2.7.4.1 2.7.4.1.1 11 ADH 1 ADH 1 4 7 129-A*-003 129-B*-001 129-E*-001P 129-G*-001 129-H*-002 129-H*-004 129-H*-005 132 242 4 129-B*-004 129-C*-005P 129-H*-003 129-H*-006 44 ADH ADH 129-C*-001P 16

More information

A A

A A 3 A B C A A 2 5 1 62 A 1 1 2 63 3 1 A proven invasive fungal diseases 1 2 3 BAL 24 : Fusarium spp. 4 2 : Candida Trichosporon B probable invasive fungal diseases Cpossible invasive fungal diseases 5 1

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr non-albicans 4 non-albicans C. glabrata, C. parapsilosis, C. tropicalis, C. krusei 4 C. guil

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr non-albicans 4 non-albicans C. glabrata, C. parapsilosis, C. tropicalis, C. krusei 4 C. guil Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 111 13 B ACTIONs Bundle ACTIONs Bundle 2009 7 ACTIONs Bundle ACTIONs project Appropriate Candidal Treatment, Implementation Of Nonneutropenic strategies

More information

2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742

2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742 MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2

More information

200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3

More information

エディロールカプセルインタビューフォーム

エディロールカプセルインタビューフォーム 2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/

More information

感染症学雑誌第80巻第6号

感染症学雑誌第80巻第6号 Candida Candida albicans Candida parapsilosis Candida glabrata Candida tropicalis C. albicans C. grabrata C. tropicalis µ Candida guilliermondii µc. parapsilosis µ Candida µcandida C. albicans µ µ µ µ

More information

untitled

untitled 1.4 特 許 状 況 - 1 - - 2 - 1.5 起 原 又 は 発 見 の 経 緯 及 び 開 発 の 経 緯 FCT CT RH ... 1.5-1... 1.5-1... 1.5-1... 1.5-1... 1.5-2... 1.5-2... 1.5-2... 1.5-3...1.5-4... 1.5-5 i 10mg FCT 1 1 6 15 5mg CT 1 1 2 6 4mg CT

More information

(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..

(1) ) ) (2) (3) (4) (5) (1) (2) b (3).. ... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32

More information

untitled

untitled 19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1

More information

Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents

Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)

More information

051

051 Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS

More information

日本化学療法学会雑誌第54巻第S-1号

日本化学療法学会雑誌第54巻第S-1号 β β Key words β Candida krusei Candida glabrata β I β Drugadministration Baselinecharacteristics Clinicalsymptom Mycologicaltests Plasmadrugconcn Adverseevents Laboratorytests ) -leadecg Clinicalphotograph

More information

日本化学療法学会雑誌第50巻新薬特集号

日本化学療法学会雑誌第50巻新薬特集号 micafungin in vitro 3 3 micafungin Candida Aspergillus Candida albicans fluconazole Candida tropicalis, Candida glabrata, Candida krusei Aspergillus 90 MIC90 0. g ml amphotericin B fluconazole itraconazole

More information

387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )

387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )

More information

CTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11

More information

日本化学療法学会雑誌第56巻第3号

日本化学療法学会雑誌第56巻第3号 β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida

More information

untitled

untitled ORYZA CERAMIDE -PTPCDP8TP20CD -WSPWSP8 -LL0.8 -PCPC8PC20 -WSPCWSPC8 -LCLC0.8 Ver.13.0HS ORYZA CERAMIDE Ver.13.0HS 1. 2. 20 NMR 4 ( 1) 1 Ver.13.0HS HO CH 2 OH O O OH OH OH C CH CH H 2 NH C O R C H C H (CH

More information

近畿中国四国農業研究センター研究報告 第7号

近畿中国四国農業研究センター研究報告 第7号 230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15

More information

/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)

/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %) / B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) (10 2 %) 0.32 0.55 0.37 0.55 95 165 115 185 (10 2 %) 0.75 (10 2 %) 0.15 (10 2 %) 0.10 10 2 % 0.10 10 2 % 0.15 10 2 % 0.10 Bands(10 2 %) 0.10 (10 9 75

More information

05-d m-4.03

05-d m-4.03 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 51(51) ABPA(M) 1 ABPM ITCZ 2 ABPA ITCZ 3 ABPA ABPM ABPM 52(52) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. 9 2004 3 6 4 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS

More information

橡DI月報200.PDF

橡DI月報200.PDF 2004.3.2 DI 22-2668 15 10 WHIWomen s Health Initiative 15 8 Million women study HRT :1.24 2 1 :1.45 14 :1.74 59 :2.17 10 :2.31 HRT 1 :1.81 HRT :1.31 HRT 65 :2.05 CKCPK http://www.pharmasys.gr.jp http://www.mhlw.go.jp

More information

取扱説明書 [F-12C]

取扱説明書 [F-12C] F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X

More information

) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky

) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky 2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)

More information

1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です

1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です 8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%

More information

日本呼吸器学会雑誌第44巻第6号

日本呼吸器学会雑誌第44巻第6号 Aspergillus β Table1 Laboratoryfindingsonadmission Hematology WB Seg Band Lymph Eos Baso RB Hb Hct Plt Biochemistry AST ALT LD ALP γ-gtp K 17,700 /mm 3 70.0 % 7.0 % 17.0 % 2.0 % 1.0 % 337 10 4 /mm 3 11.5g/dl

More information

橡サプリメント.PDF

橡サプリメント.PDF Vol.13,No.1,2004 1 Feb.200Vol.13 No.1 Vol.13,No1,2004 2 70) ph H2 P450 P450 70) Vol.13,No.1,2004 ALDH N- H2 P-450 H2 ADH ADH ADH CYP ADH 200mg/dl ADH P-450CYP CYP CYP 17)18) N- 1 48g ADH 3 Vol.13,No1,2004

More information

菌種 報告年 株数 MIC(μg/mL) Range MIC50 MIC > ( 幾何平均 ) C.tropicalis >

菌種 報告年 株数 MIC(μg/mL) Range MIC50 MIC > ( 幾何平均 ) C.tropicalis > 生物学的同等性試験におけるイトリゾール カプセル 50 のロット間での統計学 的有意差が本剤の有効性及び安全性に与える影響について イトリゾール カプセル 50 は,1993 年に内臓真菌症 ( 深在性真菌症 ), 深在性皮膚真菌症及び表在性皮膚真菌症を適応症として承認され, その後,1999 年に爪白癬等の適応を追加,2004 年及び 2006 年にはそれぞれ爪白癬のパルス療法および注射剤からの切り替えとしての新用法

More information

untitled

untitled 20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20

More information

untitled

untitled 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 24 25 26 27 1 28 1 1 2 2 3 3 k k 1 2 3 k 29 30 31 32 33 () 34 35 36 () 37 () () () 38 39 40 41 42 43 2 2 44 45 46 47 48 49 50 51 52 53 54 55

More information

125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10

125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10 . (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1

More information

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17

More information

untitled

untitled 2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1

More information

温泉の化学 1

温泉の化学 1 H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970

More information

第4次酸性雨全国調査報告書(平成16年度) -(Ⅱ)付表編-

第4次酸性雨全国調査報告書(平成16年度) -(Ⅱ)付表編- 1.12.24 P. 5.4.3.1 NO NOP. 5.4.3.2P. 5.4.3.3 P. 5.4.3.4 P. 2.18 2.19 P. 2.20 P. 2.21 P. P. 5.5.2.11 SOA P. 5.5.2.12 NO B A B 1.1 16 mm FRS Vol. 31 42006 1.2 ph 16 FRS ms/m FRS 1.3 16 Vol. 31 42006 μmol/l

More information

国試過去問集.PDF

国試過去問集.PDF I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III

More information

94.7 05.1 1 mm 2 3 1) 2) 3) 4 3- -2-3- -2-..... mm 5 ,,,, (15,000ppm) (15,000ppm) (1,000ppm) (5,000ppm) American Conference of Governmental Industrial Hygienists 3,000 6,000 12,000 18,000 6 g/ml Aspergillus

More information

,328 C 6426 H 9900 N 1700 O 2008 S , ,

,328 C 6426 H 9900 N 1700 O 2008 S , , 2458 13 4 24 1 11 9 17 1,328 C 6426 H 9900 N 1700 O 2008 S 44 145,000 148,000 10 11 27 2 13 4 24 11 9 17 (1) CD20 B CD20 (2) infusion reaction infusion-associated symptom CD20 B 1 375mg/m 2 1 4 3 Heavy

More information

スライド 1

スライド 1 平成 25 年 11 月 29 日 ( 金 ) 第 7 回大阪真菌症研究会ホテル日航大阪 深在性真菌症の治療を考える 公益財団法人鹿島病院感染症診療支援センター 菅野治重 講演内容 1 深在性真菌症について 2 抗真菌薬について 3 抗真菌薬の感受性試験について 4 耐性菌の動向 5 今後の課題 内臓真菌症の推移 FLCZ ITCZ MCFG 50.00% VRCZ 40.00% 30.00% 20.00%

More information

(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12

(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12 (1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132

More information

1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF

1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF 2003 7 3 872189 873919 IF 1998 9 PROBEAN CAP. 1 250mg Polyenephosphatidylcholine 1998 9 16 1999 7 9 1999 7 FAX IF 2003 7 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR

More information

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ , 24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998

More information

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2) (1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46

More information

i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii

More information

gtf Wnt5a-Ror2 IL-8 in vitro Ozony Tron P. gingivalis SOD ELISA Location of main occluding areas and masticatory ability in patients with reduced occlusal support 12-Methacryloyloxydodecylpyridinium bromide

More information

051

051 June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 295( 83 ) NTT 1. 2. 3. 4. CHOP-R 5. DNA 1 296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 3 1 2003 10 4 1 NTT June THE JAPANESE JOURNAL OF ANTIBIOTICS

More information

: / FDA HBsAg HIV 1/2 HCV : QMS : 3.5% IgM () 1.0% H317 - H334 - : : :: : QMS Everolimus : 6.4% (II) H400 - H % SDS QMS EDTA (K 3 ) EDTA (K 2 )

: / FDA HBsAg HIV 1/2 HCV : QMS : 3.5% IgM () 1.0% H317 - H334 - : : :: : QMS Everolimus : 6.4% (II) H400 - H % SDS QMS EDTA (K 3 ) EDTA (K 2 ) QMS (EVER) 0373852 (QMS) QMS QMS X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X

More information

C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %

C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % % 2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up

More information

M41 JP Manual.indd

M41 JP Manual.indd i ii iii iv v vi vii 1 No / A-B EQ 2 MIC REC REC00001.WAV Stereo CH:01 0:00:00 1:50:00 3 4 5 6 7 8 9 10 11 12 1 1 F F A A 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 Φ 35 36 37 38

More information

参考資料5 農薬評価書 メタアルデヒド(食品安全委員会資料)

参考資料5 農薬評価書 メタアルデヒド(食品安全委員会資料) 1 3 3 4 5. 6 1. 6 2. 6 3. 6 4. 6 5. 6 6. 6 7. 6. 7 1. 7 2. 8 (1) 8 (2) 9 (3) 9 (4) 10 (5) 10 3. 11 (1) 11 (2) 11 (3) 11 (4) 12 4. 12 (1) 12 (2) 12 (3) 13 5. 13 6. 13 7. 14 8. 15 9. 16 10. 16 (1) 90 16-1

More information

001-029_”÷’X

001-029_”÷’X 54 2012 1 29 Kimori Daisuke Kamijo Takashi Takahashi Akira 1993 19951997 2001 10 1993 1999 1992 54 2012 1993 20 LDH BUNCRE UA CPK GOT CPK LDH UA CPK LDH UA CPK 1989 2001 2000 1989 1995 2003 2005 1989 54

More information

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b) 2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)

More information

日本化学療法学会雑誌第51巻第2号

日本化学療法学会雑誌第51巻第2号 piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC

More information

橡DI月報178.PDF

橡DI月報178.PDF 2002.5.10. DI 22-2668 HCV HCV 1 1 375mg/ 13 60mg 20mg 1 20mg 1 750mg 1 400mg 3 1 2 7 IAB IAB IAB IAB IAB HIV ( ) HIV CYP3A4 HIV ( ) CYP3A4 WBC CK CK 1) 2) Torsades de Pointes K ) ALT AST -GTP CYP2C9 CYP2C19

More information

第65回日本化学療法学会東日本支部総会 抄録

第65回日本化学療法学会東日本支部総会 抄録 鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma

More information

- 108 -

- 108 - 3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg

More information

untitled

untitled 1% 1 mg 1 mg 2 CTD 6 Section 2.6.1 Introduction 2.6.1 H 1 descarboethoxyloratadinesch 34117 7.9 SCH 34117 2.6.1-1 O OC 2 H 5 Cl N N JAN Loratadine (JANINN) ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]

More information

_02三浦.indd

_02三浦.indd 36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut

More information

第十五改正日本薬局方第一追補

第十五改正日本薬局方第一追補 316 3 5 7 9 9 9 12 13 14 14 14 23 23 23 24 24 29 29 29 35 37 131 161 173 193 194 198 200 205 3 37 37 37 38 38 38 39 39 40 40 41 42 43 43 45 46 47 48 49 50 51 52 52 53 54 54 54 55 56 58 58 59 60 60 61 61

More information

sick contact1l

sick contact1l Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5

More information

21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty

More information

HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly

HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu

More information

mg (1) (2) QT (3) 1 400mg 1 1 2

mg (1) (2) QT (3) 1 400mg 1 1 2 17 8 10 400mg 14 9 30 1 400mg 1 C21H24FN3O4 HCl 437.89 1 6 8 7 [(4aS, 7aS) [3,4 b] 6 ] 4 1,4 3 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridine -6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic

More information

<4D F736F F D F8DCC97918C7B82CC8C8C897490B689BB8A AB8FF382CC908488DA2E646F63>

<4D F736F F D F8DCC97918C7B82CC8C8C897490B689BB8A AB8FF382CC908488DA2E646F63> 1 8 4 26 2 ( )(0 20 )(21 64 ) 4 (TP) (GOT GPT) (ALP)(LDH) (Amyl)(CPK) (T cho) (TG) (NEFA) HDL (HDL c) (Na) (K) (cl) (Ca)(P) (Crea)(UA) (Glu) 19 TP GOT LDH T cho NEFA.HDL c K UA GPT LDH CPK T cho TG NEFA

More information

2009年133巻3号3月号.indb

2009年133巻3号3月号.indb Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine

More information

アクテムラインタビューフォーム

アクテムラインタビューフォーム 2009 2 6 876399 IF 1998 9 FAX 80mg 1 4mL 80mg 200mg 1 10mL200mg 400mg 1 20mL400mg JAN TocilizumabGenetical RecombinationJAN 200mg 80400mg 2007 9 10 2008 4 16 2007 12 21 2008 6 13 2005 6 13 2008 6 13 2009

More information

日本呼吸器学会雑誌第44巻第10号

日本呼吸器学会雑誌第44巻第10号 β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG

More information

ケイセントラ_製品情報概要_H1-4_収載_新発売

ケイセントラ_製品情報概要_H1-4_収載_新発売 DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1

More information

cladribine 2-CdA ADA DCF HCL IFN- MTD LD50 LD90 DLT MDACC RWJPRI NHL ATL CLL 2-CdATP 5 -NT dckase (2-chloro-2 -deoxyadenosine) adenosine deaminase deoxycoformycin( ) hairy cell leukemia - (interferon alfa)

More information

untitled

untitled 1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,

More information

高脂血症の検査

高脂血症の検査 35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH

More information

グリセオール注インタビューフォーム

グリセオール注インタビューフォーム 2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10

More information

土壌の観察・実験テキスト −土壌を調べよう!−

土壌の観察・実験テキスト −土壌を調べよう!− ( ) 2006 7 20 i 21 1962 1969 1987 1992 2005 65 1972 1977 1997 1977 1998 1982 1998 2002 2004 2005 SPP 1999 ii 1 g cm m 6378km ( ) 4.2, 4.3 5.1 7.1 8.1 4.1 7.3, 7.4 7.1 1 2 7.1 8.2 2 5 6 1, 2 2.3 4.2, 4.3

More information

112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6

112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6 Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 111 53 8 8 1. Ph-ALL Liposomal amphotericin B 1 2. CBT MCFG L-AMBAML 2 112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6

More information

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI 20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old

More information

600mg 600mg CTD 2 2.5 2.5 Page 3 2.5...7 2.5.1...7 2.5.2...27 2.5.3...28 2.5.4...42 2.5.5...55 2.5.6...79 2.5.7...97 2.5 Page 5 73 67 31 48 48A 102 104 105 106 ALP ALT(GPT) AST(GOT) AUC AUEC BID BUN

More information

小児感染免疫第25巻第2号

小児感染免疫第25巻第2号 Vol. 25No. 2145 1,2 1 1 1 1 2 2 2 TFLX 9 TFLX 450 mg16.6 mgkg TFLX 30 kg TFLX 2009 10 TFLX 1 1 2 3,4 TFLX 9 22 6 18 19 TFLX 450 mg150 mg 1 1 1 3 16.6 mgkg 20 20 0 21 3 135.0 cm0.1 S.D. 27.0 kg0.8 S.D.

More information

IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF

IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF 2009 2 1 872612 IF 1998 9 IODINE M DISINFECTANT SOLUTION 10 10w/v 100mL 10g( 1g) PovidoneIodine 2008 10 15 2008 12 19 2009 1 6 IF 2008 12 IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF

More information

後期化学_04_酸塩基pH

後期化学_04_酸塩基pH 2011 ( ) ph H3O + H + H3O + HCl H3O + HCl + H2O H3O + + Cl HCl H + + Cl OH OH NaOH OH NaOH Na + + OH NH3 OH NH3 + H2O NH4 + + OH 1 H + OH H + H + * 1 NH3 HCl NH4Cl NH4Cl NH3 + Cl NH3 + HCl NH4 + + Cl.

More information

Acecide_ProductsInformation2010PDF.indd

Acecide_ProductsInformation2010PDF.indd 53-0115-00-4PDF 53-0115-00-4PDF INDEX 1 3 9 11 12 16 21 38 39 40 42 43 44 45 46 47 53-0115-00-4PDF 3 1 Critical Semicritical Noncritical Disinfection Sterilization 53-0115-00-4PDF 2 53-0115-00-4PDF O =

More information

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 () - 1 - - 2 - - 3 - - 4 - - 5 - 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57

More information

Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl

Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl ( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11

More information

t 492 t mg/l 30 mg/l BOD 95 OH = cm 3 / sec 25 8 OH /cm 3 12 = ph ph

t 492 t mg/l 30 mg/l BOD 95 OH = cm 3 / sec 25 8 OH /cm 3 12 = ph ph 2-1 200169 2740 CAS 110-49-6 1103 2- O H 3 C C O CH 2 CH 2 O CH 3 C 5 H 10 O 3 118.13 200168 2-1 99 2-1. 2 2, 3-65 2, 3 144145 45 o.c. 3 392 3 1.512.3 d19 1.009 2 4.07 = 1 30 Pa 0.23 mmhg20 2 4 log Pow0.10

More information

1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET i BALF ii CVF i ii BALF i ii iii BALF i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4)

1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET i BALF ii CVF i ii BALF i ii iii BALF i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4) 1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET ibalf ii CVF i iibalf i ii iiibalf i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4) ET CVF (5) (6) 3) (1)in vitro 2. 1)ONO-5046Na (1) (2) (3) (4)

More information

- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...

- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8... 取 扱 説 明 書 - - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...9...11 - - - - - - - - - - - - - - - - -

More information

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1 11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1

More information

L- 11 12 13 15 15 17 17 18 21 23 25 25 27 29 29 30 31 32 32 33 36 36 36 37 37 37 38 39 39 40 42 42 45 46 48 10 48 11 49 11 50 50 50 51 51 51 51 52 52 53 53-54 12 55 55 57 28 3 6 4 8 7 6 100% 3 30 p.5760

More information

日本化学療法学会雑誌第58巻第2号

日本化学療法学会雑誌第58巻第2号 Key words β Candida Table1. MCFGCPAstudygroup Investigator (representative) YoshitsuguMiyazaki NaoyukiMiyashita RyoichiAmitani KenjiOgawa AtsuyukiKurashima ToshiroKiguchi MichiakiMishima YuichiInoue HiroshiSaito

More information

IMUSERA 3 3 4 4 5 5 5 5 6 1 1 12 18 25 25 31 31 31 31 32 32 37 43 43 45 48 48 48 48 49 5 1 2 3 4 3 4 1.56mg.5mg D- 3 15.9mm 5.8mm.96g FTY.5mg FTY.5mg OH NH2 OH H3C HCI 5 6 7 BCG Torsades de pointes a 2

More information

橡99-24_00 アリルアルコール.PDF

橡99-24_00 アリルアルコール.PDF 1 9924 2260 CAS 107186 H 2 C CH CH 2 OH 2- -1- C 3 H 6 O 58.08 1 99 1. 2, 3 3, 4, 5-129 96-97 2 21c.c. 24o.c. 2 6, 7 378 6, 7 2.5-18 d 20 4 0.8540 2, 5 2.00 = 1 2.7 kpa 20 mmhg204.3 kpa 32 mmhg30 4 log

More information

i

i 14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7

More information